Infectious Disease · Clinical trials
Influenza Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About influenza — and why its trials are hard
Influenza is an acute respiratory illness caused by influenza A and B viruses, driving seasonal epidemics with substantial hospitalization and mortality, especially among older adults, young children, and people with chronic conditions. Prevention centers on annual vaccination reformulated to match circulating strains. For treatment, neuraminidase inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza) were approved in 1999, and inhaled/IV peramivir later; these shorten symptom duration by roughly a day when started early and may reduce complications. Baloxavir marboxil (Xofluza), approved in 2018, is a single-dose cap-dependent endonuclease inhibitor that rapidly reduces viral shedding. Antiviral benefit is greatest when started within 48 hours of symptom onset. Vaccine effectiveness varies year to year with strain match, typically ranging from about 40% to 60% in well-matched seasons. Resistance can emerge, notably treatment-emergent PA/I38 substitutions reducing baloxavir susceptibility, underscoring ongoing surveillance needs.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Oseltamivir (Tamiflu) | 1999 | Oral neuraminidase inhibitor for treatment and prophylaxis of influenza A and B | Phase 3 treatment trials (e.g., Treanor et al., JAMA 2000) | Time to alleviation of influenza symptoms | Reduced symptom duration by roughly 1 day (about 24-33 hours) versus placebo when started within 48 hours of onset. |
| Baloxavir marboxil (Xofluza) | 2018 | Single-dose oral cap-dependent endonuclease inhibitor for acute uncomplicated influenza | CAPSTONE-1 (phase 3, NEJM 2018) | Time to alleviation of symptoms | Comparable symptom relief to oseltamivir and faster than placebo (median ~53.7 vs 80.2 hours), with markedly faster reduction in viral load; treatment-emergent PA/I38 resistance observed. |
| Zanamivir (Relenza) | 1999 | Inhaled neuraminidase inhibitor for treatment of influenza A and B (avoid in reactive airway disease) | Phase 3 inhaled zanamivir trials (MIST and related, 1998-2000) | Time to alleviation of symptoms | Shortened symptom duration by approximately 1-1.5 days versus placebo when started early. |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in influenza development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Pimodivir (PB2 inhibitor) — Phase 3 program (Janssen), including hospitalized/high-risk influenza A studies | Development discontinued; failed to demonstrate sufficient added clinical benefit over standard of care | Insufficient incremental efficacy (including combined with oseltamivir) to justify continued development. |
Choosing the right endpoint
Primary endpoints that matter in influenza trials
- Time to alleviation of symptoms — Standard efficacy endpoint for antivirals in uncomplicated influenza; benefit is time-sensitive to early dosing.
- Reduction in viral load / shedding — Baloxavir reduces shedding faster than neuraminidase inhibitors; relevant to transmission.
- Vaccine efficacy/effectiveness against confirmed influenza — Varies by season and strain match, typically ~40-60% in matched years.
- Influenza-related complications/hospitalization — Key outcome in high-risk populations; antiviral effect on complications is less robustly established.
How iNGENū runs influenza trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Influenza clinical trials — FAQs
How soon must antivirals be started to work?
What makes baloxavir different?
Do antivirals replace the flu vaccine?
Ready to discuss your influenza trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal